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Background Previous studies at the Dow AgroSciences (Formerly Ivon Watkins-Dow) plant in New Plymouth,
NewZealand, hadraisedconcernsaboutthecancer riskin asubsetofworkersatthesitewithpotential
exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. As the plant had been involved in the synthesis and
formulation of a wide range of agrochemicals and their feedstocks, we examined the mortality risk for
all workers at the site.
Aims To quantify the mortality hazards arising from employment at the Dow AgroSciences agrochemical
production site in New Plymouth, New Zealand.
Methods Workers employed between 1 January 1969 and 1 October 2003 were followed up to the end of 2004.
Standardized mortality ratios (SMRs) were calculated using national mortality rates by employment
duration, sex, period of hire and latency.
Results A total of 1754 employees were followed during the study period and 247 deaths were observed. The
all causes and all cancers SMRs were 0.97 (95% CI 0.85–1.10) and 1.01 (95% CI 0.80–1.27), re-
spectively. Mortality due to all causes was higher for short-term workers (SMR 1.23, 95% CI 0.91–
1.62) than long-term workers (SMR 0.92, 95% CI 0.80–1.06) and women had lower death rates than
men. Analyses by latency and period of hire did not show any patterns consistent with an adverse
impact of occupational exposures.
Conclusions The mortality experience of workers at the site was similar to the rest of New Zealand.
Key words Chemical industry; cohort studies; dioxins; mortality; occupational exposure; risk assessment.
Introduction
TheformerIvonWatkins-Dowplant,nowDowAgroScien-
cesNewZealand[1],hasbeeninoperationatthesamesite
since 1962 making a diverse range of agrochemical prod-
ucts. Initially, the plant manufactured 2,4-dichlorophe-
noxy acetic acid and later 2,4,5-trichlorophenoxy acetic
acid (2,4,5-T) and 4-chloro2-methylphenoxyacetic acid.
The2,4,5-trichlorophenolfeedstockfor2,4,5-Twasman-
ufactured from 1969, and smaller amounts of 2-methyl-
4-chlorophenoxybutyric acid were manufactured from
the early 1970s. In addition to phenoxy herbicides, nu-
merous other pesticides and chemical raw materials were
handled on the site: these included the sodium salt of
2,4,6-TCP, picloram, atrazine, simazine, amitrole and
dichloropropionic acid. In 1987, the TCP plant closed
and 2,4,5-T production ceased in 1988. The dioxin,
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), can be an
unwanted contaminant in TCP and 2,4,5-T. Figure 1
provides the chemical structure of TCDD, TCP and
2,4,5-T. The current manufacturing activities are mostly
centred around the formulation and packaging of insecti-
cides, herbicides, fungicides and spraying oil.
Because of the potential exposure to TCDD, some
workers at the plant were included in an international co-
hort of 18 910 phenoxy herbicide sprayers and produc-
tion workers designed to evaluate health effects and
exposure to TCDD. This study was carried out in 10
countries by the International Agency for Research on
Cancer and the results, published in 1991, indicated that
soft tissue sarcomas and non-Hodgkin’s lymphoma were
greater than expected among workers with exposure to
2,4,5-T [2].
The New Plymouth study subgroup included 1038
men and women who worked at least 1 month between
1969 and 1984, with vital status follow-up to 1987.
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teria as exposed to phenoxies, probably exposed, with
‘unknown exposure’ or unexposed. There were 782
employees who were considered exposed to phenoxy her-
bicides or trichlorophenol, with some workers involved in
warehousing of products at other New Zealand sites. The
unexposed workers were employed outside the produc-
tion areas such as in administrative positions. This study
found a small excess of all cancers combined but no in-
crease in lung cancer, soft tissue sarcoma or non-Hodg-
kin’s lymphoma, cancers which have been associated with
TCDD exposure in some studies. The study was recently
updated with follow-up to 2000 [3]. The ﬁndings were
similar to the earlier study although there were more mul-
tiple myeloma deaths than expected among workers with
potential dioxin exposure.
Given these reports about the health risks at the New
Plymouthsite, theprincipalaimofthisstudywastoquan-
tify the overall mortality hazard from employment there.
The objectives were to identify and include all the
employees who worked at the plant between 1969 and
2003, follow the vital status of these workers to the end
of2004anddetermineifworkersatthesitehavemortality
levels different from the New Zealand population. This is
the ﬁrst study in a series which will examine the health of
these workers.
Methods
Work history records were used to identify all the employ-
eeswhoworkedforatleast1dayattheNewPlymouthsite
between 1 January 1969 and 1 October 2003: the latter
being the date that the work history records were col-
lected. In the analysis, 23 individuals who had missing
dates of birth were excluded, and 9 people lacking infor-
mation on sex were assumed to be male. The total num-
ber of workers in the study was 1754.
Vital status for each study member was determined
from 1 January 1969 to 31 December 2004. The search
was based on the New Zealand Health Information
Service (NZHIS) Mortality Collection [4], in which
deaths registered in New Zealand from 1988 onwards
are held in the electronic mortality database, and data
from 1970 to 1987 are archived and are available on
request. Deaths occurring between 1969 and 1987 were
matched to work records using an algorithm which
required an exact match on date of birth and ranked
minor errors in the spelling of surnames and forenames,
nine being a perfect match, with eight and seven being
minor differences in surname or forename. All matches
were examined, and matches of seven to nine proved
acceptable. From 1988 onwards, searches were based
on the National Health Index number on the mortality
database, unique to each individual. We then carried
out additional searches based on the last known address
on the employee database, following name and address
changes using the Electoral Roll and Habitation Index
[5], Telephone Book, Companies Ofﬁce [6], ‘Terranet’
property information database [7] and search engines
on the Internet [8,9].
Additional deaths up to 1990 were sought from the
Registrar-General’s Index to Deaths. If a person was
not known to be alive at the study end date (i.e. on the
electoral roll), an additional search was made through
births, deaths and marriages. Follow-up ended on 31 De-
cember 2004, at the date of death, or for those who had
left New Zealand, or could not be traced, at the date they
werelastknowntobeinthecountry.NZHISprovidedthe
coded underlying causes of death for all deaths in the
study [10].
The expected numbers of deaths adjusted for age, gen-
der and calendar year were calculated using the Occu-
pational Mortality Cohort Analysis Program [11]. The
New Zealand national mortality rates, obtained from
NZHIS,wereusedasthereferencepopulation.Standard-
ized mortality ratios (SMRs) and exact 95% conﬁdence
intervals (CIs) were calculated for major causes of death
and cancer. Person-years for the study members were ac-
cumulated across 5-year age calendar year-speciﬁc catego-
ries from the date of entry into the study until the end of
follow-up. Analyses were carried out by duration of em-
ployment, sex, latency and period of hire. For the duration
of employment analyses, we divided workers into two
groups. The ﬁrst group included workers employed for
#3 months to account for seasonal and short-term work-
ers.Thesecondgroupincludedthoseworkerswhoworked
for $3 month. Latency was deﬁned as the period between
the day last worked and the date of death, the end of study
date and the date lost to follow-up or emigration, which-
ever came ﬁrst [12]. Latency of less than and greater than
15 years and period of hire pre-1976 and post-1975 were
chosen to examine possible exposure effects while having
a reasonable number of person-years in each stratum.
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Figure 1. Chemical structures for TCDD, 2,4,5-trichlorophenol and
2,4,5-T.
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From the total of 1754 eligible persons, 247 deaths were
observed. Twenty-two per cent of the cohort was lost to
follow-up as shownin Table 1. This included 392 individ-
uals, among which 156 (9%) were known to have emi-
grated before the study end date.
Among all employees (Table 2), all cause mortality,
SMR 0.97 (95% CI 0.85–1.10), and all cancer mortality,
SMR 1.01 (95% CI 0.80–1.27), were close to expected
levels. There were no statistically signiﬁcant differences
in any cause of death compared to the New Zealand pop-
ulation. Approximately, one-third of the deaths were due
to heart disease and were close to expected levels (SMR
1.02, 95% CI 0.81–1.27). There were more than ex-
pected numbers of deaths due to cancers of the digestive
system (27 observed versus 22.8 expected) and lympho-
haematopoietic cancers (8 observed versus 6.6 expected).
On the other hand, some speciﬁc cancers occurred at less
than expected rates, such as lung cancer (15 observed
versus 17.3 expected), breast cancer (2 observed versus
3.5 expected) and prostate cancer (3 observed versus 5.6
expected).
The rates for those who had worked at the site for ,3
months(short-termemployees)weregenerallyhigher than
those who worked for $3m o n t h s( l o n g - t e r me m p l o y e e s ) ,
short-term employees showing an all causes SMR of 1.23
(95% CI 0.91–1.62). This included a statistically signiﬁ-
cant excess of all cancers of the digestive system, SMR
2.52 (95% CI 1.15–4.78), reﬂected by an increased risk
for all the subsites in this category except cancer of the
large intestine. The increased risk was not only limited
to malignant neoplasm but also occurred from heart dis-
ease, cirrhosis of the liver and motor vehicle accidents.
Conversely,thelong-term employees exhibited,ingeneral,
lowermortalityrateswithmostcausesatlessthanexpected
rates. Theseincludedall causes (SMR0.92, 95%CI0.80–
1.06), allcancers (SMR 0.98,95%CI0.75–1.26),cancers
of the digestive system (SMR 0.94, 95% CI 0.56–1.48)
and heart disease (SMR 0.94, 95% CI 0.72–1.20). All
eight lymphohaematopoietic cancers in the cohort were
found in the long-term employees, producing a slightly el-
evated SMR of 1.21 (95% CI 0.52–2.39).
Those with $15 years of latency had lower mortality
from all causes, all cancers and all heart disease as shown
in Table 3. Deaths from all lymphohaematopoietic tu-
mours remained raised in this group (7 observed versus
4.7 expected), mostly as a result of non-Hodgkin’s lym-
phoma (SMR 2.09, 95% CI 0.57–5.35) and multiple my-
eloma (SMR 2.10, 95% CI 0.26–7.60). Accidents,
including motor vehicle accidents, were also greater than
expected, as were asthma, nephritis and nephrosis.
There were only 26 deaths in those employed after
1975, as shown in Table 4, with all causes, all cancers
and all heart disease SMRs at 0.74 (95% CI 0.48–
1.08), 0.62 (95% CI 0.25–1.28) and 0.60 (95% CI
0.20–1.41), respectively. Those employed prior to 1976
had SMRs close to expected levels for the same causes.
There were fewer deaths among females (27) than
males (220) as shown in Table 5. Females had lower
all causes mortality, SMR 0.68 (95% CI 0.45–1.00), than
males, SMR 1.02 (95% CI 0.89–1.17). A decrease in fe-
male all cancer mortality was evident, with an SMR of
0.52 (95% CI 0.22–1.02), as compared to a male rate
of 1.14 (95% CI 0.90–1.45). Cause-speciﬁc rates among
the women were, however, imprecise due to the small
numbers of observed and expected deaths.
Discussion
Wefoundoverallthatworkersinthe study populationhad
death rates similar to the rest of New Zealand. Employ-
ment duration accounted for the greatest differences in
observed mortality rates: relative to long-term workers,
those who were employed for ,3 months had higher
death rates for many causes including all causes, all can-
cers, ischaemic heart disease and all accidents. In addi-
tion, among these short-term workers, cancers of the
digestive system were greater than expected especially
for rectal cancer, oesophageal cancer and pancreatic can-
cer. In contrast, workers employed for .3 months had
mortality levels consistent with the rest of New Zealand.
These ﬁndings of higher death rates among short-term
workers have been reported in other studies, attributed
to the healthy worker effect [13] and lifestyle factors, es-
pecially alcohol use and tobacco [14–16]. Since the long-
term workershad mortality and cancer rates similar to the
New Zealand population, it is unlikely that brief work-
place exposures contributed signiﬁcantly to the mortality
rates seen in the short-term workers.
Women working at the site had low mortality rates
compared to women in the rest of New Zealand (SMR
0.68, 95% CI 0.45–1.00). These low rates among women
Table 1. Vital status follow-up of study group
Category n (%) PY contributed
Alive
a 1115 (64) 31 084
Dead 247 (15) 4579
COD provided by NZHIS 247
Lost to follow-up
b,c 392 (22) 2679
Unknown 236 (13)
Emigrated 156 (9)
Total 1754
38 343
COD, cause of death; PY, person-years.
aFifteen people died after the end-of-study date.
bThree people died overseas after their end-of-follow-up date, which was deter-
mined as the end of their last NZ Dow job or last known date of NZ residence.
cPerson-years potentially lost to follow-up 5 7735.
D. I. MCBRIDE ET AL.: MORTALITY IN EMPLOYEES AT A NZ AGROCHEMICAL MANUFACTURING SITE 257at the site are attributable to low cancer and heart disease
rates. Although there were few person-years of follow-up,
these low rates for women in chemical plants have been
seen in other studies [17–20].
One potential limitation of this study is the 22% loss to
follow-up. However, our levels of loss are similar to other
New Zealand studies.Muchofthe lossto follow-upisdue
to the high rate of emigration which occurs in New
Table 2. SMR and 95% CI by duration of employment
Cause of death Employment duration
$3 months ,3 months All durations
Obs/exp SMR 95% CI Obs/exp SMR 95% CI Obs/exp SMR 95% CI
All causes of death 197/213.7 0.92 (0.80–1.06) 50/40.6 1.23 (0.91–1.62) 247/254.4 0.97 (0.85–1.10)
All malignant neoplasms 62/63.3 0.98 (0.75–1.26) 14/11.8 1.19 (0.65–2.00) 76/75.1 1.01 (0.80–1.27)
Cancer of buccal cavity
and pharynx
3/1.2 2.45 (0.51–7.15) 0/0.3 – (0.00–14.46) 3/1.5 2.03 (0.42–5.92)
Cancer of digestive organs
and peritoneum
18/19.2 0.94 (0.56–1.48) 9/3.6 2.52* (1.15–4.78) 27/22.8 1.19 (0.78–1.73)
Cancer of oesophagus 3/1.7 1.73 (0.36–5.05) 2/0.3 6.05 (0.73–21.86) 5/2.1 2.42 (0.79–5.65)
Cancer of stomach 5/3.1 1.61 (0.52–3.75) 1/0.6 1.75 (0.04–9.75) 6/3.7 1.63 (0.60–3.55)
Cancer of large intestine 3/5.9 0.51 (0.11–1.49) 0/1.1 – (0.00–3.49) 3/6.9 0.43 (0.09–1.26)
Cancer of rectum 5/3.3 1.51 (0.49–3.52) 3/0.6 4.88* (1.01–14.25) 8/3.9 2.03 (0.88–4.01)
Cancer of biliary passages
and liver primary
1/1.6 0.64 (0.02–3.58) 1/0.3 3.08 (0.08–17.19) 2/1.9 1.06 (0.13–3.85)
Cancer of pancreas 1/2.6 0.39 (0.01–2.18) 2/0.5 4.31 (0.52–15.58) 3/3.0 0.99 (0.21–2.90)
Cancer of respiratory system 16/15.5 1.03 (0.59–1.67) 2/2.8 0.72 (0.09–2.60) 18/18.3 0.98 (0.58–1.55)
Cancer of larynx 2/0.4 4.71 (0.57–17.03) 0/0.1 – (0.00–47.16) 2/0.5 3.98 (0.48–14.38)
Cancer of bronchus, trachea
and lung
13/14.7 0.89 (0.47–1.51) 2/2.6 0.77 (0.09–2.77) 15/17.3 0.87 (0.49–1.43)
Malignant melanoma of skin 1/2.2 0.46 (0.01–2.59) 1/0.5 2.01 (0.05–11.18) 2/2.7 0.75 (0.09–2.72)
Soft tissue sarcoma 1/0.3 3.03 (0.08–16.89) 0/0.1 – (0.00–49.29) 1/0.4 2.47 (0.06–13.77)
Cancer of breast (female only) 2/3.1 0.65 (0.08–2.36) 0/0.5 – (0.00–8.14) 2/3.5 0.57 (0.07–2.06)
Cancer of cervix uteri
(female only)
1/0.5 1.82 (0.05–10.15) 0/0.1 – (0.00–42.52) 1/0.6 1.57 (0.04–8.77)
Cancer of prostate (male only) 3/4.8 0.62 (0.13–1.82) 0/0.8 – (0.00–4.67) 3/506 0.54 (0.11–1.56)
Cancer of kidney 2/1.4 1.39 (0.17–5.03) 1/0.3 3.48 (0.09–19.39) 3/1.7 1.74 (0.36–5.09)
Cancer of bladder and other
urinary organs
1/1.4 0.72 (0.02–3.99) 0/0.2 – (0.00–15.94) 1/1.6 0.62 (0.02–3.43)
Cancer of central nervous system 3/2.2 1.38 (0.29–4.03) 1/0.5 1.99 (0.05–11.10) 4/2.7 1.50 (0.41–3.83)
Cancer of all lymphatic and
haematopoietic tissue
8/5.5 1.46 (0.63–2.88) 0/1.1 – (0.00–3.32) 8/6.6 1.21 (0.52–2.39)
Hodgkin’s disease 1/0.3 3.83 (0.10–21.32) 0/0.1 – (0.00–62.04) 1/0.3 3.12 (0.08–17.37)
Non-Hodgkin’s lymphoma 4/2.1 1.92 (0.52–4.91) 0/0.4 – (0.00–8.58) 4/2.5 1.59 (0.43–4.07)
Leukaemia and aleukaemia 1/2.0 0.49 (0.01–2.74) 0/0.4 – (0.00–8.73) 1/2.5 0.41 (0.01–2.27)
Multiple myeloma 2/1.0 1.96 (0.24–7.09) 0/0.2 – (0.00–19.75) 2/1.2 1.66 (0.20–5.99)
Diabetes mellitus 4/4.6 0.87 (0.24–2.23) 1/0.9 1.15 (0.03–6.40) 5/5.5 0.92 (0.30–2.14)
Cerebrovascular disease 13/15.4 0.84 (0.45–1.44) 4/2.4 1.65 (0.45–4.21) 17/17.9 0.95 (0.55–1.52)
All heart disease 64/68.3 0.94 (0.72–1.20) 18/11.9 1.51 (0.89–2.38) 82/80.3 1.02 (0.81–1.27)
Ischaemic heart disease 59/58.9 1.00 (0.76–1.29) 16/10.1 1.58 (0.90–2.56) 75/69 1.09 (0.86–1.36)
Non-malignant respiratory
disease
13/17.5 0.74 (0.40–1.27) 1/2.8 0.36 (0.01–2.02) 14/20.3 0.69 (0.38–1.16)
Bronchitis 2/4.5 0.45 (0.05–1.61) 0/0.7 – (0.00–4.97) 2/5.2 0.38 (0.05–1.38)
Emphysema 2/1.6 1.23 (0.15–4.43) 0/0.3 – (0.00–14.69) 2/1.9 1.06 (0.13–3.84)
Asthma 3/1.5 1.97 (0.41–5.77) 1/0.3 3.07 (0.08–17.10) 4/1.8 2.17 (0.59–5.55)
Cirrhosis of liver 2/1.7 1.16 (0.14–4.20) 2/0.4 5.58 (0.68–20.14) 4/2.1 1.92 (0.52–4.93)
Nephritis and nephrosis 2/1.5 1.30 (0.16–4.68) 1/0.3 3.74 (0.09–20.82) 3/1.8 1.66 (0.34–4.84)
All external causes of death 13/19.0 0.69 (0.37–1.17) 8/6.0 1.33 (0.57–2.61) 21/25 0.84 (0.52–1.28)
Accidents 10/12.7 0.79 (0.38–1.45) 7/4.0 1.74 (0.70–3.59) 17/16.7 1.02 (0.59–1.63)
Motor vehicle accidents 4/6.9 0.58 (0.16–1.49) 6/2.3 2.58 (0.95–5.60) 10/9.2 1.09 (0.52–2.00)
Suicides 2/5.3 0.38 (0.05–1.37) 1/1.7 0.59 (0.02–3.27) 3/7.0 0.43 (0.09–1.26)
Obs/exp, observed/expected.
*P , 0.05.
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igratedduringthestudyperiod.Thetrueemigrationrateis
likely to have been .9% since we only counted emigrants
we could locate. Since emigrants do not contribute to the
national mortality rates, their withdrawal from follow-up
does not introduce a bias into risk estimation. The true
number lost to follow-up of no more than 236 (or 13%
of the cohort),and likely tobemuchless,isconsistentwith
Table 3. SMR and 95% CI by latency
Cause of death Latency
15 years latency ,15 years
Obs/exp SMR 95% CI Obs/exp SMR 95% CI
All causes of death 166/175.0 0.95 (0.81–1.10) 81/79.3 1.02 (0.81–1.27)
All malignant neoplasms 53/55.0 0.96 (0.72–1.26) 23/20.1 1.14 (0.72–1.71)
Cancer of buccal cavity
and pharynx
2/1.0 1.92 (0.23–6.92) 1/0.4 2.29 (0.06–12.75)
Cancer of digestive organs
and peritoneum
18/16.7 1.08 (0.64–1.70) 9/6.1 1.48 (0.68–2.81)
Cancer of oesophagus 4/1.6 2.51 (0.68–6.42) 1/0.5 2.13 (0.05–11.87)
Cancer of stomach 6/2.5 2.36 (0.87–5.14) 0/1.1 – (0.00–3.25)
Cancer of large intestine 1/5.0 0.20 (0.01–1.10) 2/1.9 1.06 (0.13–3.83)
Cancer of rectum 4/2.9 1.40 (0.38–3.59) 4/1.1 3.70* (1.01–9.46)
Cancer of biliary passages
and liver primary
2/1.4 1.43 (0.17–5.18) 0/0.5 – (0.00–7.62)
Cancer of pancreas 1/2.2 0.45 (0.01–2.53) 2/0.8 2.45 (0.30–8.85)
Cancer of respiratory system 11/13.3 0.83 (0.41–1.48) 7/5.1 1.39 (0.56–2.86)
Cancer of larynx 1/0.3 2.87 (0.07–15.98) 1/0.2 6.50 (0.16–36.23)
Cancer of bronchus, trachea
and lung
10/12.5 0.80 (0.38–1.47) 5/4.8 1.05 (0.34–2.44)
Malignant melanoma of skin 0/1.8 – (0.00–2.01) 2/0.8 2.43 (0.30–8.79)
Soft tissue sarcoma 1/0.2 4.13 (0.10–22.99) 0/0.2 – (0.00–22.73)
Cancer of breast (female only) 1/2.3 0.43 (0.01–2.38) 1/1.2 0.85 (0.02–4.75)
Cancer of cervix uteri
(female only)
1/0.4 2.85 (0.07–15.87) 0/0.3 – (0.00–12.98)
Cancer of prostate (male only) 3/4.8 0.62 (0.13–1.81) 0/0.8 – (0.00–4.83)
Cancer of kidney 3/1.3 2.37 (0.49–6.93) 0/0.5 – (0.00–8.07)
Cancer of bladder and other
urinary organs
1/1.3 0.78 (0.02–4.36) 0/0.3 – (0.00–10.55)
Cancer of central nervous system 3/1.7 1.73 (0.36–5.06) 1/0.9 1.06 (0.03–5.90)
Cancer of all lymphatic,
haematopoietic tissue
7/4.7 1.48 (0.60–3.05) 1/1.9 0.54 (0.01–2.98)
Hodgkin’s disease 0/0.1 – (0.00–26.62) 1/0.2 5.49 (0.14–30.57)
Non-Hodgkin’s lymphoma 4/1.9 2.09 (0.57–5.35) 0/0.6 – (0.00–6.14)
Leukaemia and aleukaemia 1/1.7 0.60 (0.02–3.34) 0/0.8 – (0.00–4.71)
Multiple myeloma 2/1.0 2.10 (0.26–7.60) 0/0.3 – (0.00–14.44)
Diabetes mellitus 4/4.3 0.93 (0.25–2.39) 1/1.2 0.85 (0.02–4.74)
Cerebrovascular disease 11/13.1 0.84 (0.42–1.50) 6/4.8 1.26 (0.46–2.75)
All heart disease 53/55.7 0.95 (0.71–1.25) 29/24.6 1.18 (0.79–1.69)
Ischaemic heart disease 49/47.5 1.03 (0.76–1.36) 26/21.5 1.21 (0.79–1.77)
Non-malignant respiratory
disease
10/15.2 0.66 (0.32–1.21) 4/5.1 0.78 (0.21–2.00)
Bronchitis 2/3.9 0.52 (0.06–1.87) 0/1.4 – (0.00–2.71)
Emphysema 1/1.4 0.72 (0.02–4.03) 1/0.5 2.00 (0.05–11.16)
Asthma 2/0.9 2.20 (0.27–7.94) 2/0.9 2.14 (0.26–7.72)
Cirrhosis of liver 1/1.3 0.80 (0.02–4.43) 3/0.8 3.65 (0.75–10.66)
Nephritis and nephrosis 3/1.4 2.11 (0.44–6.17) 0/0.4 – (0.00–9.47)
All external causes of death 11/10.0 1.10 (0.55–1.96) 10/15.0 0.67 (0.32–1.23)
Accidents 10/6.2 1.62 (0.77–2.97) 7/10.6 0.66 (0.27–1.37)
Motor vehicle accidents 6/3.0 1.98 (0.73–4.30) 4/6.2 0.65 (0.18–1.66)
Suicides 1/3.3 0.30 (0.01–1.69) 2/3.7 0.54 (0.07–1.96)
Obs/exp, observed/expected.
*P , 0.05.
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thoselosttofollow-upmayhavehighermortalityratesthan
therestofthestudypopulation,wefeelthatthelossissmall
enough to have little inﬂuence on risk estimates.
Another potential limitation of this study is size. While
we have included all workers employed at this site from
1969 to near the end of 2003, there are some causes of
death which we could not credibly evaluate because they
are relatively rare. For example, we did observe 1 death
from soft tissue sarcoma versus 0.4 expected. This cancer
has been related to TCDD exposure in some studies.
With the small number of observed and expected deaths
Table 4. SMR and 95% CI by date of hire
Cause of death Date of hire
Pre-1976 Post-1975
Obs/exp SMR 95% CI Obs/exp SMR 95% CI
All causes of death 221/219.0 1.01 (0.88–1.15) 26/35.4 0.74 (0.48–1.08)
All malignant neoplasms 69/63.9 1.08 (0.84–1.37) 7/11.2 0.62 (0.25–1.28)
Cancer of buccal cavity
and pharynx
3/1.3 2.38 (0.49–6.97) 0/0.2 – (0.00–16.55)
Cancer of digestive organs
and peritoneum
25/19.6 1.28 (0.83–1.89) 2/3.2 0.62 (0.08–2.25)
Cancer of oesophagus 5/1.8 2.77 (0.90–6.46) 0/0.3 – (0.00–14.21)
Cancer of stomach 6/3.2 1.87 (0.69–4.08) 0/0.5 – (0.00–7.75)
Cancer of large intestine 2/5.9 0.34 (0.04–1.22) 1/1.0 1.00 (0.03–5.58)
Cancer of rectum 7/3.4 2.06 (0.83–4.24) 1/0.5 1.88 (0.05–10.45)
Cancer of biliary passages
and liver primary
2/1.6 1.28 (0.16–4.63) 0/0.3 – (0.00–11.62)
Cancer of pancreas 3/2.6 1.15 (0.24–3.35) 0/0.4 – (0.00–9.09)
Cancer of respiratory system 16/16.1 1.00 (0.57–1.62) 2/2.3 0.88 (0.11–3.19)
Cancer of larynx 2/0.4 4.45 (0.54–16.06) 0/0.1 – (0.00–69.99)
Cancer of bronchus, trachea
and lung
13/15.2 0.86 (0.46–1.47) 2/2.1 0.94 (0.11–3.40)
Malignant melanoma of skin 1/2.1 0.47 (0.01–2.62) 1/0.5 1.90 (0.05–10.58)
Soft tissue sarcoma 1/0.3 3.12 (0.08–17.41) 0/0.1 – (0.00–43.56)
Cancer of breast (female only) 2/2.5 0.81 (0.10–2.93) 0/1.0 – (0.00–3.54)
Cancer of cervix uteri (female only) 1/0.4 2.25 (0.06–12.53) 0/0.2 – (0.00–19.34)
Cancer of prostate (male only) 3/5.2 0.58 (0.12–1.68) 0/0.4 – (0.00–9.36)
Cancer of kidney 3/1.5 2.05 (0.42–6.00) 0/0.3 – (0.00–14.04)
Cancer of bladder and other
urinary organs
1/1.5 0.68 (0.02–3.77) 0/0.1 – (0.00–24.66)
Cancer of central nervous system 3/2.1 1.41 (0.29–4.11) 1/0.5 1.84 (0.05–10.24)
Cancer of all lymphatic,
haematopoietic tissue
7/5.5 1.27 (0.51–2.62) 1/1.1 0.92 (0.02–5.14)
Hodgkin’s disease 1/0.3 3.76 (0.09–20.95) 0/0.1 – (0.00–67.24)
Non-Hodgkin’s lymphoma 3/2.1 1.44 (0.30–4.21) 1/0.4 2.29 (0.06–12.76)
Leukaemia and aleukaemia 1/2.0 0.49 (0.01–2.74) 0/0.4 – (0.00–8.80)
Multiple myeloma 2/1.0 1.92 (0.23–6.93) 0/0.2 – (0.00–22.55)
Diabetes mellitus 5/4.6 1.08 (0.35–2.51) 0/0.8 – (0.00–4.54)
Cerebrovascular disease 13/16.2 0.80 (0.43–1.37) 4/1.7 2.39 (0.65–6.11)
All heart disease 77/72.0 1.07 (0.84–1.34) 5/8.3 0.60 (0.20–1.41)
Ischaemic heart disease 70/62.3 1.12 (0.88–1.42) 5/6.7 0.74 (0.24–1.73)
Non-malignant respiratory disease 13/18.4 0.71 (0.38–1.21) 1/1.8 0.54 (0.01–3.01)
Inﬂuenza and pneumonia 2/3.9 0.51 (0.06–1.86) 0/0.2 – (0.00–16.12)
Bronchitis 2/4.7 0.43 (0.05–1.54) 0/0.5 – (0.00–6.93)
Emphysema 2/1.7 1.16 (0.14–4.19) 0/0.2 – (0.00–23.13)
Asthma 3/1.5 1.98 (0.41–5.79) 1/0.3 3.01 (0.08–16.78)
Cirrhosis of liver 2/1.8 1.13 (0.14–4.10) 0/0.2 – (0.00–19.23)
All external causes of death 14/17.7 0.79 (0.43–1.32) 7/7.3 0.96 (0.39–1.99)
Accidents 6/6.3 0.95 (0.35–2.07) 4/2.9 1.40 (0.38–3.57)
Suicides 2/4.7 0.42 (0.05–1.53) 1/2.3 0.44 (0.01–2.45)
Obs/exp, observed/expected.
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or refute an impact of workpla c ee x p o s u r eo ns o f tt i s s u e
sarcoma. Such an evaluation for rare causes of death will
have to wait for larger studies with detailed exposure
evaluations.
A previous study at this site examined mortality levels
in a subset of the workers in our study who were poten-
tially exposed to dioxins as contaminants of the 2,4,5-T
production. The investigators reported that all causes
mortality in production workers was not greater than
expected; however, there were more cancers than
expected including a statistically signiﬁcant increase in
deaths from multiple myeloma (3 observed versus 0.5
expected). In contrast, we found all cancers at expected
levels and 2 deaths from multiple myeloma versus 1.2
expected. While the tracing methods used and numbers
lost to follow-up were similar in both the studies, the dif-
ferences in cohort deﬁnitions and subgroups studied
could have accounted for the differences in observed
deaths.
Table 5. SMR and 95% CI by sex
Cause of death Sex
Male Female
Obs/exp SMR 95% CI Obs/exp SMR 95% CI
All causes of death 220/214.9 1.02 (0.89–1.17) 27/39.5 0.68* (0.45–1.00)
All malignant neoplasms 68/59.6 1.14 (0.89–1.45) 8/15.5 0.52 (0.22–1.02)
Cancer of buccal cavity and pharynx 3/1.3 2.23 (0.46–6.51) 0/0.1 – (0.00–27.63)
Cancer of digestive organs and peritoneum 25/18.9 1.32 (0.86–1.95) 2/3.9 0.52 (0.06–1.86)
Cancer of oesophagus 5/1.9 2.68 (0.87–6.26) 0/0.2 – (0.00–18.21)
Cancer of stomach 5/3.2 1.55 (0.50–3.62) 1/0.5 2.18 (0.05–12.12)
Cancer of large intestine 3/5.4 0.56 (0.12–1.63) 0/1.5 – (0.00–2.38)
Cancer of rectum 7/3.3 2.09 (0.84–4.31) 1/0.6 1.70 (0.04–9.45)
Cancer of biliary passages and liver primary 2/1.6 1.25 (0.15–4.52) 0/0.3 – (0.00–13.21)
Cancer of pancreas 3/2.5 1.20 (0.25–3.52) 0/0.5 – (0.00–6.98)
Cancer of respiratory system 16/15.9 1.00 (0.57–1.63) 2/2.4 0.84 (0.10–3.04)
Cancer of larynx 2/0.5 4.16 (0.50–15.01) 0/0.0 – (0.00–173.85)
Cancer of bronchus, trachea and lung 13/15.0 0.87 (0.46–1.48) 2/2.3 0.87 (0.11–3.13)
Malignant melanoma of skin 2/2.2 0.91 (0.11–3.29) 0/0.5 – (0.00–8.08)
Soft tissue sarcoma 1/0.3 3.14 (0.08–17.52) 0/0.1 – (0.00–42.54)
Cancer of breast (female only) 1/0.0 – – 1/3.5 0.29 (0.01–1.59)
Cancer of cervix uteri (female only) 0/0.0 – – 1/0.6 1.57 (0.04–8.77)
Cancer of prostate (male only) 3/5.6 0.54 (0.11–1.56) 0/0.0 – –
Cancer of kidney 3/1.5 2.01 (0.42–5.88) 0/0.2 – (0.00–15.95)
Cancer of bladder and other urinary organs 1/1.5 0.68 (0.02–3.76) 0/0.1 – (0.00–25.32)
Cancer of central nervous system 3/2.2 1.38 (0.28–4.02) 1/0.5 2.03 (0.05–11.30)
Cancer of all lymphatic, haematopoietic tissue 7/5.4 1.30 (0.52–2.68) 1/1.2 0.83 (0.02–4.60)
Hodgkin’s disease 0/0.3 – (0.00–13.58) 1/0.0 20.30 (0.51–113.11)
Non-Hodgkin’s lymphoma 4/2.0 1.97 (0.54–5.05) 0/0.5 – (0.00–7.56)
Leukaemia and aleukaemia 1/2.0 0.50 (0.01–2.78) 0/0.4 – (0.00–8.22)
Multiple myeloma 2/1.0 2.02 (0.24–7.30) 0/0.2 – (0.00–17.10)
Diabetes mellitus 5/4.4 1.13 (0.37–2.64) 0/1.0 – (0.00–3.54)
Cerebrovascular disease 14/14.5 0.97 (0.53–1.62) 3/3.4 0.89 (0.18–2.59)
All heart disease 77/71.8 1.07 (0.85–1.34) 5/8.5 0.59 (0.19–1.37)
Ischaemic heart disease 71/62.3 1.14 (0.89–1.44) 4/6.7 0.60 (0.16–1.53)
Non-malignant respiratory disease 12/17.3 0.70 (0.36–1.21) 2/3.0 0.66 (0.08–2.40)
Inﬂuenza and pneumonia 2/3.6 0.55 (0.07–1.98) 0/0.5 – (0.00–7.71)
Bronchitis 1/4.4 0.23 (0.01–1.26) 1/0.8 1.25 (0.03–6.94)
Emphysema 2/1.7 1.21 (0.15–4.38) 0/0.2 – (0.00–15.86)
Asthma 3/1.4 2.17 (0.45–6.35) 1/0.5 2.15 (0.05–11.96)
Cirrhosis of liver 4/1.8 2.20 (0.60–5.63) 0/0.3 – (0.00–14.25)
Nephritis and nephrosis 2/1.5 1.31 (0.16–4.75) 1/0.3 3.46 (0.09–19.28)
All external causes of death 18/22.3 0.81 (0.48–1.28) 3/2.7 1.11 (0.23–3.25)
Accidents 14/15.0 0.93 (0.51–1.56) 3/1.7 1.75 (0.36–5.11)
Motor vehicle accidents 9/8.1 1.12 (0.51–2.12) 1/1.1 0.89 (0.02–4.98)
Suicides 3/6.2 0.48 (0.10–1.41) 0/0.8 – (0.00–4.74)
Obs/exp, observed/expected.
*P , 0.05.
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sures at the plant, we did not classify the cohort with re-
spect to particular chemicals or contaminants, but looked
for effects through period of hire and latency. Period of
hire is useful for isolating potential occupational expo-
sures. The bulk of employment occurred in the decade
following the inception of the study and the majority of
those exposed to 2,4,5 TCP and 2,4,5,-T would have
been included in the pre-1976 analysis. Most carcinogens
are assumed to have long latency periods and analyses by
latency are useful for examining potential workplace
effects. We did observe higher total cancer rates in the
pre-1976 period (SMR 1.08, 95% CI 0.84–1.37) than
in the post-1975 period (SMR 0.62, 95% CI 0.25–
1.28). However, the rates for total cancers were lower
in the longer latency period (SMR 0.96, 95% CI 0.72–
1.26) than in the shorter latency period (SMR 1.14,
95% CI 0.72–1.71). We also observed four deaths from
non-Hodgkin’s lymphoma in this study. Three deaths
of non-Hodgkin’s lymphoma occurred in the pre-1976
group (SMR 1.44, 95% CI 0.30–4.21) and one death
in the post-1975 group (SMR 2.29, 95% CI 0.06–
12.76). All non-Hodgkin’s lymphoma deaths occurred
in the longer latency group (SMR 2.09, 95% CI 0.57–
5.36).
As a surveillance tool, the principal objective of this
analysis was to quantify the potential hazard of employ-
ment at the site rather than of any speciﬁc chemical expo-
sures. We observed rates for all causes, all malignant
neoplasms and many other causes of death to be similar
to the New Zealand general population rates, but higher
than expected rates were consistently observed for short-
term employees.
In summary, the results of our study indicate that there
is no excess mortality risk for employees who worked at
the New Plymouth site. The most critical step in address-
ing mortality is, however, to look at speciﬁc exposures in
detail which will be the subject of future studies. This re-
port establishes the basis from which this can be done.
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